An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Pemetrexed

Criteria

Inclusion Criteria:

• Non-small cell lung cancer (NSCLC) (any histologic type)

• Stage IIIB or IV disease

• Should have had 1 line of chemotherapy for Metastatic disease

• Adequate hematologic, hepatic and renal function

• Measurable or evaluable disease

Exclusion Criteria:

• Pregnant or lactating females